Journal Information
Vol. 57. Issue 2.
Pages 81-82 (February 2021)
Vol. 57. Issue 2.
Pages 81-82 (February 2021)
Editorial
Full text access
Spanish implementation of the new international alpha-1 anitrypsin deficiency international registry: The European Alpha-1 Research Collaboration (EARCO)
Implantación en España del nuevo registro internacional de déficit de alfa-1-antitripsina European Alpha-1-Research Collaboration (EARCO)
Visits
...
Miriam Barrechegurena,b, María Torres-Duranc,d, Francisco Casas-Maldonadoe,f, Marc Miravitllesa,g,
Corresponding author
marcm@separ.es

Corresponding author.
a Servicio de Neumología, Hospital Universitari Vall d´Hebron, Barcelona, Spain
b Miembro de la European Alpha-1-Research Collaboration (EARCO)
c Servicio de Neumología, Hospital Álvaro Cunqueiro, EOXI Vigo, Vigo, Pontevedra, Spain
d Coordinadora del Registro Español de pacientes con Dèficit de Alfa-1-Antitripsina (REDAAT)
e Servicio de Neumología, Hospital Universitario San Cecilio, Granada, Spain
f Coordinador del REDAAT entre 2016 y 2019
g Coordinador de la European Alpha-1-Research Collaboration (EARCO)
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text

The main function of alpha-1-antitrypsin (AAT) is to protect the lung from the action of proteases. To do this, it behaves as an acute phase reactant and is also endowed with anti-inflammatory activity1,2. Alpha-1-antitrypsin deficiency (AATD) is a congenital disease that presents with low serum AAT levels and predisposes patients to the development of pulmonary emphysema3,4.

AATD is defined as a minority disease, although it is not really that uncommon. In Spain, estimates suggest that there are some 14,000 individuals with severe homozygous deficits (Pi*ZZ)5, but this figure is far from the number of cases actually diagnosed in our country6. The minority nature of AATD and its low diagnostic rate mean that the number of cases seen in each hospital is often very low, making it difficult to gain experience in this disease. For this reason, the European Respiratory Society (ERS), in a statement in 2017, recommended that these patients be diagnosed, treated, and followed up in reference centers7.

Another consequence of the low prevalence of AATD is the difficulty of conducting clinical trials or observational studies with sufficient sample sizes, and many questions on the etiology, pathogenesis, treatment, and natural history of the disease remain unresolved8–10. To address this problem, both healthcare professionals and patients have agreed that setting up an international registry of patients with AATD aimed at obtaining prospective information on the natural history of the disease is a priority7.

To respond to this need, 2017 saw the launch of the European Alpha-1-Research Collaboration (EARCO, https://www.earco.eu/registry/), an ERS Clinical Research Collaboration (CRC)11, aimed at establishing a collaborative network of international experts including clinicians, researchers and patients, in collaboration with the European Lung Foundation (ELF) and the European Respiratory Network (ERN)-Lung groups12. The main objective and core of this initiative is the EARCO registry, which will begin recruiting patients in 2020. This will be an international, observational registry that will include longitudinal, prospective and standardized data needed to: (a) generate long-term, high-quality clinical data covering an international population of individuals with AATD in all age groups and all stages of disease severity; (b) better understand the natural history and prognosis of AATD in order to develop prognostic tools that support medical decision-making; (c) investigate the impact of augmentation therapy on the progress of emphysema and quality of life and mortality; and (d) learn more about the course of the disease in patients with genotypes other than Pi*ZZ. This will include patients with a diagnosis of severe AATD defined by a serum AAT level <11 μM (50 mg/dl) and/or combinations of ZZ, SZ alleles and heterozygotes or homozygotes composed of combinations of other null or rare deficient variants. The EARCO registry hopes to collect detailed information on 1,000 patients from at least 10 countries during the first year, expanding to 3,000 patients from more than 20 countries during the first 3 years13.

The Spanish DAAT Registry (REDAAT) has been active since 1992. It now includes data from about 800 individuals and has helped determine the geographical distribution and clinical characteristics of patients6. However, the follow-up of registered individuals has been irregular, with only 44% of patients attending a median of only 2 follow-up visits6, so the information obtained on the natural history of the disease has been very limited14.

For this reason, the EARCO registry is an opportunity for REDAAT to join this international initiative, use this platform to improve the quantity and quality of the data collected, and ensure long-term prospective follow-up of the individuals included. An important challenge is to ensure that data obtained during the REDAAT years are not lost in this new merger with EARCO, and for this purpose a strategy common to other countries that also have their own registry has been designed. From the moment EARCO is implemented, all individuals diagnosed in Spain who meet the inclusion criteria will be registered directly and uniquely in EARCO, whether they are newly diagnosed or already registered in REDAAT. Historical data from existing registries will not be entered in EARCO; instead, it is a new project that will start from scratch.

Annual monitoring is an essential part of achieving the EARCO goals. For this reason, automatic reminders will be sent to all participating investigators, and an EARCO manager will be appointed who, among other things, will be responsible for ensuring maximum compliance with follow-up visits and reviewing the quality of the data entered.

Patients included from Spanish centers will be assigned a pseudonym that will identify their country of origin, and the REDAAT coordinator will be able to access them for review and analysis. Thus, it will be possible to integrate these data with all the historical data that was collected by REDAAT, to ensure that the valuable data obtained during the course of REDAAT will continue to be available for research.

The new European data protection directive has posed a major challenge for the development of disease registries and has greatly complicated all logistics, and required collaboration and data transfer contracts to be set up15. For this reason, although no minimum number of cases for participation has been specified, it is logical that inclusion of patients should be concentrated in reference centers or centers with a significant number of cases to compensate the efforts necessary for participation in EARCO. We are convinced that this effort will be worthwhile and that EARCO will become the international reference registry for AATD and the source of future research projects in this “not so rare” disease.

Conflict of interests

Marc Miravitlles has received honoraria for speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, Sandoz, Zambon, CSL Behring, Grifols and Novartis; honoraria for consultancy services from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, Kamada, CSL Behring, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, TEVA, pH Pharma, Novartis, Sanofi and Grifols, and research funding from GlaxoSmithKline and Grifols.

Miriam Barrecheguren has received honoraria for speaking engagements from Grifols, CSL Behring, Menarini and GlaxoSmithKline, and for consultancy services from GlaxoSmithKline, Novartis and Gebro Pharma.

Francisco Casas has received honoraria for speaking engagements from AstraZeneca, Bial, Boehringer Ingelheim, Chiesi, Ferrer, Gebro Pharma, GlaxoSmithKline, Esteve Laboratories, Menarini, Novartis, Rovi, Sandoz, TEVA, Zambon, CSL Behring and Grifols.

María Torres-Durán has received honoraria for speaking engagements from Grifols, CSL Behring, Esteve, Ferrer and GlaxoSmithKline, and for consultancy services from Grifols and CSL Behring.

References
[1]
P. Ellis, A. Turner.
What do Alpha-1 antitrypsin levels tell us about chronic inflammation in COPD?.
Arch Bronconeumol, 56 (2020), pp. 72-73
[2]
S. Janciauskiene, D.S. DeLuca, M. Barrecheguren, T. Welte, M. Miravitlles, Scientific Committee; Participating sites and coordinators.
Serum levels of Alpha1-antitrypsin and their relationship with COPD in the general Spanish population.
Arch Bronconeumol, 56 (2020), pp. 76-83
[3]
M. Torres-Durán, J.L. Lopez-Campos, M. Barrecheguren, M. Miravitlles, B. Martinez-Delgado, S. Castillo, et al.
Alpha-1 antitrypsin deficiency: outstanding questions and future directions.
Orphanet J Rare Dis, 13 (2018), pp. 114
[4]
A. Perciaccante, P. Charlier, C. Negri, A. Coralli, O. Appenzeller, R. Bianucci.
Lessons from the past: some histories of Alpha-1 antitrypsin deficiency before its discovery.
[5]
I. Blanco, P. Bueno, I. Diego, S. Pérez-Holanda, F. Casas-Maldonado, C. Esquinas, et al.
Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update.
Int J Chron Obstruct Pulmon Dis, 12 (2017), pp. 561-569
[6]
B. Lara, I. Blanco, M.T. Martínez, E. Rodríguez, A. Bustamante, F. Casas, et al.
Spanish Registry of patients with alpha-1 antitrypsin deficiency: database evaluation and population analysis.
Arch Bronconeumol, 53 (2017), pp. 13-18
[7]
M. Miravitlles, A. Dirksen, I. Ferrarotti, V. Koblizek, P. Lange, R. Mahadeva, et al.
European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency.
[8]
J.M. Hernández Pérez, J.A. Pérez Pérez.
Changes in the melting point of hybridization probes used for genotyping in Alpha-1 antitrypsin deficiency do not always imply errors.
Arch Bronconeumol, 55 (2019), pp. 339-340
[9]
R.A. Tubío-Pérez, M. Blanco-Pérez, C. Ramos-Hernández, M. Torres-Durán.
Alpha-1 antitrypsin deficiency associated with the PI*Q0ourém Allele in a 2-year-old girl and family study. An unusual case.
Arch Bronconeumol, 54 (2018), pp. 228-230
[10]
M. Barrecheguren, M. Miravitlles.
Augmentation therapy for emphysema due to alpha-1 antitrypsin deficiency: pro.
Arch Bronconeumol, 54 (2018), pp. 363-364
[11]
C. Brightling, C. Genton, W. Bill, T. Welte, M. Gaga, E. Heuvelin, et al.
ERS Clinical Research Collaborations: underpinning research excellence.
[12]
M. Miravitlles, J. Chorostowska-Wynimko, I. Ferrarotti, N.G. McElvaney, K. O’Hara, J. Stolk, et al.
The European Alpha-1 Research Collaboration (EARCO): a new ERS Clinical Research Collaboration to promote research in alpha-1 antitrypsin deficiency.
[13]
T. Greulich, A. Altraja, M. Barrecheguren, R. Bals, J. Chlumsky, J. Chorostowska- Wynimko, et al.
Protocol for the EARCO-Registry: a Pan-European observational study in patients with alpha-1 antitrypsin deficiency.
ERJ Open Res, 6 (2020),
[14]
C. Esquinas, S. Serreri, M. Barrecheguren, E. Rodriguez, A. Nuñez, F. Casas-Maldonado, et al.
Long-term evolution of lung function in individuals with Alpha-1 Antitrypsin Deficiency from the Spanish Registry.
Int J Chron Obstruct Pulm Dis, 13 (2018), pp. 1001-1007
[15]
P.G.H. Metnitz, P. Zajic, A. Rhodes.
The General Data Protection Regulation and its effect on epidemiological and observational research.
Lancet Respir Med, 8 (2020), pp. 23-24

Please cite this article as: Barrecheguren M, Torres-Duran M, Casas-Maldonado F, Miravitlles M. Implantación en España del nuevo registro internacional de déficit de alfa-1-antitripsina European Alpha-1-Research Collaboration (EARCO). Arch Bronconeumol. 2021;57:81–82.

Archivos de Bronconeumología

Subscribe to our newsletter

Article options
Tools

Are you a health professional able to prescribe or dispense drugs?